Highlights

• Mayne Pharma secured exclusive Australian rights to Blissel® under a five-year licence agreement.
• Australia’s topical vaginal estrogen market was approximately AU$27 million in 2025, with a two-year CAGR of 16%.
• Blissel® is targeted for an FY28 launch using Mayne Pharma’s existing women’s health commercial infrastructure.

Mayne Pharma Expands Women’s Health PortfolioMayne Pharma Group Limited (ASX: MYX) announced that it had completed an exclusive licensing agreement with global specialty pharmaceutical company Italfarmaco S.A. for Blissel® in Australia. The announcement comes as MYX shares trade at a current market price (CMP) of AU$3.050, down 0.326%.

The five-year arrangement gives Mayne Pharma exclusive Australian rights to register, market and distribute Blissel®, an ultra-low-dose estriol vaginal gel used to treat vaginal atrophy associated with menopause. The company will hold the Australian marketing authorisation and manage all commercialisation activities, while Italfarmaco will retain beneficial ownership and continue to oversee manufacturing.Why Blissel® Matters for Mayne Pharma?Blissel® contains estriol at a concentration of 50 micrograms per gram and is formulated as a vaginal mucoadhesive gel. According to Mayne Pharma, the product has almost negligible systemic absorption and there are currently no registered ultra-low-dose or gel estriol formulations in Australia.

The addition broadens Mayne Pharma’s Australian women’s health offering alongside NEXTSTELLIS®. Importantly, the company plans to commercialise Blissel® through its existing women’s health team, potentially allowing it to expand the portfolio without requiring a substantial new commercial platform.AU$27 Million Market Offers Growth OpportunityThe commercial backdrop appears supportive. Mayne Pharma estimates that Australia’s market for topical vaginal estrogen menopause hormone therapies was approximately AU$27 million in 2025. The category recorded a two-year compound annual growth rate of 16%.

Management links this expansion to stronger clinical recognition of treatable menopause symptoms, Australia’s ageing population and a greater willingness among patients to seek treatment. These trends could provide a favourable demand environment as Blissel® approaches commercialisation.FY28 Launch Provides the Next MilestoneMayne Pharma is targeting an Australian launch in FY28 through its established commercial team. Management expects the product to develop into a meaningful contributor to the international segment’s sales mix over subsequent years.

The agreement includes upfront signing and regulatory milestone payments, additional one-off sales milestones capped at EUR300,000 in aggregate as net sales increase, and an ongoing royalty linked to net sales, subject to an agreed floor price.Existing Infrastructure Could Support Efficient ExpansionA notable feature of the agreement is its fit with Mayne Pharma’s established operating footprint. The company already has commercial capabilities in Australian women’s health, meaning Blissel® can potentially leverage existing prescriber and pharmacy relationships rather than requiring a separate sales network.

This creates an opportunity for incremental portfolio growth while limiting the need for a material expansion in the cost base. However, the commercial contribution remains dependent on regulatory progress, launch execution and eventual product adoption.What Could Drive MYX Shares Next?The Blissel® agreement expands Mayne Pharma’s exposure to a growing Australian menopause treatment category while adding another product to its women’s health portfolio. The AU$27 million addressable market and 16% two-year growth rate provide a constructive industry backdrop, while the planned use of existing infrastructure may support operating efficiency.

With MYX trading at AU$3.050 after declining 0.326%, investor attention could now centre on regulatory milestones, progress toward the FY28 launch and the eventual contribution of Blissel® to International sales. The agreement adds longer-term commercial optionality, although meaningful financial benefits are likely to depend on successful registration, market uptake and disciplined execution.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au